Achaete-scute complex homolog 1 (ASCL1)

Achaete-scute complex homolog 1 (ASCL1) is a basic helix-loop-helix (bHLH) transcription factor that serves as a master regulator of neurogenesis and neuroendocrine cell differentiation (UniProt P50553). It acts as a pioneer factor, capable of binding to closed chromatin and recruiting other factors to initiate gene expression programs essential for neuronal development (PubMed: 26748121). In the context of human disease, ASCL1 is a key driver in small cell lung cancer (SCLC), particularly the SCLC-A subtype, where it promotes tumor cell survival and neuroendocrine features (PubMed: 31110054). Because transcription factors like ASCL1 lack traditional small-molecule binding pockets, they are often considered difficult to target directly. However, emerging therapeutic strategies focus on indirect inhibition via epigenetic regulators like LSD1 or transcriptional machinery components like CDK7/9 (PubMed: 30651635). ASCL1 expression is also utilized as a diagnostic biomarker to classify neuroendocrine tumors and guide treatment selection.

Other names

ASH1HASH1MASH1bHLHa46Achaete-scute homolog 1

ASCL1 acts as a pioneer transcription factor that binds to E-box motifs (CANNTG) in DNA to promote the expression of genes involved in neuroendocrine differentiation and cell cycle progression. Therapeutic strategies focus on indirect inhibition by disrupting its transcriptional complex through epigenetic modulators like LSD1 inhibitors or by targeting the transcriptional machinery such as CDK7/9.